Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer

摘要: Background: Gefitinib (Iressa®) is active as a single agent in the treatment of select patients with recurrent non-small cell lung cancer (NSCLC). The clinical characteristics treated gefitinib on an Expanded Access Program (EAP) at our institution identified predictive variables associated better outcome. Patients and methods: (n=199) advanced NSCLC were (250 mg) upon progression chemotherapy. Baseline patient were: median age, 69 years; males, 57%; adenocarcinoma, 56%. Results: Partial responses noted two (1%) disease stabilization 66 (35%) patients. survival (MS) was 5.9 months [95% confidence interval (CI) 4.1-7.1] time to 3 (95% CI 2.0-3.0). factors analyzed gender, skin rash, diarrhea, tumor histology performance status (PS). who developed rash (any grade) had MS 10.8 versus 4.0 for those without (P<0.0001, log rank test). PS 0, 1 2 8.4, 6.2 2.8 months, respectively (P <0.0002). other did not impact survival. Conclusions: Occurence baseline 0/1 improved institution.